BMC gastroenterology · 2026
Outcomes for a digital prescription mobile application for adults with irritable bowel syndrome: an uncontrolled trial.
Клиническое исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Butt Mohsin F, Reghefaoui Maiss, Bush Debbie, Aliyu Abdulsalam, Darie Ana-Maria, Mohanan Aleesha, Sibelli Alice, Card Timothy R, Corsetti Maura
Аннотация
BACKGROUND: Behavioral therapies are effective in the management of irritable bowel syndrome (IBS). Mahana™ IBS is a mobile phone application designed to deliver 10 sessions (10-12 weeks) of gut-directed cognitive behavioral therapy (CBT) to adults with IBS.
OBJECTIVES: To evaluate patient compliance with the Mahana™ mobile phone CBT application and the change in gastrointestinal and psychological symptoms in a real-world UK setting.
METHODS: This single-center prospective study recruited adults with Rome IV IBS from a tertiary care outpatient setting. At baseline and 12-week follow-up, patients completed questionnaires assessing gastrointestinal symptoms (IBS symptom severity scale [IBS-SSS]), depression (patient health questionnaire-9 [PHQ-9]), and anxiety (generalized anxiety disorder-7 [GAD-7]).
RESULTS: Thirty patients (20/30 female, mean [SD] age 44.57 [14.70]) consented to treatment and completed pre-intervention questionnaires, among whom 20 (66.7%) provided follow-up questionnaire data. Among the 20 individuals with two-point data, there was a statistically significant reduction in the IBS-SSS (P<0.001), GAD-7 (P=0.02), and PHQ-9 (P=0.04) scores. Fourteen (70%) patients reported a clinically significant improvement (≥50 point reduction) in the IBS-SSS; these individuals tended to be older (P=0.04) and male (P=0.04). Patients with IBS-diarrhea reported the greatest improvement in the IBS-SSS versus those with IBS-constipation and IBS-mixed subtypes. The baseline IBS-SSS (P=0.35), GAD-7 (P=0.19) and PHQ-9 (P=0.19) scores were not significantly different between persons who completed the entire CBT intervention versus those who did not.
CONCLUSION: This study provides preliminary evidence that the Mahana™ IBS CBT application is associated with a statistically significant improvement in gastrointestinal and psychological symptoms in a real-world UK clinical setting.
TRIAL REGISTRATION: This trial was registered on ClinicalTrials.gov (trial registration number: NCT07008404) on 6 June 2025.
OBJECTIVES: To evaluate patient compliance with the Mahana™ mobile phone CBT application and the change in gastrointestinal and psychological symptoms in a real-world UK setting.
METHODS: This single-center prospective study recruited adults with Rome IV IBS from a tertiary care outpatient setting. At baseline and 12-week follow-up, patients completed questionnaires assessing gastrointestinal symptoms (IBS symptom severity scale [IBS-SSS]), depression (patient health questionnaire-9 [PHQ-9]), and anxiety (generalized anxiety disorder-7 [GAD-7]).
RESULTS: Thirty patients (20/30 female, mean [SD] age 44.57 [14.70]) consented to treatment and completed pre-intervention questionnaires, among whom 20 (66.7%) provided follow-up questionnaire data. Among the 20 individuals with two-point data, there was a statistically significant reduction in the IBS-SSS (P<0.001), GAD-7 (P=0.02), and PHQ-9 (P=0.04) scores. Fourteen (70%) patients reported a clinically significant improvement (≥50 point reduction) in the IBS-SSS; these individuals tended to be older (P=0.04) and male (P=0.04). Patients with IBS-diarrhea reported the greatest improvement in the IBS-SSS versus those with IBS-constipation and IBS-mixed subtypes. The baseline IBS-SSS (P=0.35), GAD-7 (P=0.19) and PHQ-9 (P=0.19) scores were not significantly different between persons who completed the entire CBT intervention versus those who did not.
CONCLUSION: This study provides preliminary evidence that the Mahana™ IBS CBT application is associated with a statistically significant improvement in gastrointestinal and psychological symptoms in a real-world UK clinical setting.
TRIAL REGISTRATION: This trial was registered on ClinicalTrials.gov (trial registration number: NCT07008404) on 6 June 2025.